ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 579,81
-0,69%
Dow Jones
40 755,86
1,35%
DAX
18 519,15
-0,44%
Brent Oil
83,46
-1,04%
Bitcoin
64 525,39
-0,50%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
13/12/201616h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016NASDAQ:SMMTSummit Therapeutics Inc
21/11/201616h11Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
16/11/201613h00GlobeNewswire Inc.Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDNASDAQ:SMMTSummit Therapeutics Inc
06/10/201613h00GlobeNewswire Inc.Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle SocietyNASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h05Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h01GlobeNewswire Inc.Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for Europea...NASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h00GlobeNewswire Inc.Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Ut...NASDAQ:SMMTSummit Therapeutics Inc
27/09/201613h00GlobeNewswire Inc.Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyNASDAQ:SMMTSummit Therapeutics Inc
26/09/201613h00GlobeNewswire Inc.Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyNASDAQ:SMMTSummit Therapeutics Inc
12/09/201613h00GlobeNewswire Inc.Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy CommunityNASDAQ:SMMTSummit Therapeutics Inc
08/09/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
07/09/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:SMMTSummit Therapeutics Inc
05/09/201613h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016NASDAQ:SMMTSummit Therapeutics Inc
09/08/201613h00GlobeNewswire Inc.Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate EzutromidNASDAQ:SMMTSummit Therapeutics Inc
05/08/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/06/201618h30GlobeNewswire Inc.Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionNASDAQ:SMMTSummit Therapeutics Inc
17/06/201613h00GlobeNewswire Inc.First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMDNASDAQ:SMMTSummit Therapeutics Inc
16/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
08/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Host Utrophin R&D Day 15 June 2016NASDAQ:SMMTSummit Therapeutics Inc
06/06/201612h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
02/06/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
31/05/201613h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016NASDAQ:SMMTSummit Therapeutics Inc
26/05/201622h17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:SMMTSummit Therapeutics Inc
23/05/201613h00GlobeNewswire Inc.Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM...NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
10/05/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
06/05/201613h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
28/04/201617h46GlobeNewswire Inc.Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the...NASDAQ:SMMTSummit Therapeutics Inc
28/04/201613h00GlobeNewswire Inc.Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

BIT
P1Y664
NLBNPIT1Y664 20240920 3
LSE
UB89
Citi Fun 25
TSX
VET
Vermilion Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés